Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Tomoya Yokota"'
Autor:
Yoshiyuki Iida, Takanori Kawabata, Tomoya Yokota, Hirofumi Ogawa, Takashi Mukaigawa, Yusuke Onozawa, Tsuyoshi Onoe, Satoshi Hamauchi, Hirofumi Yasui, Ari Nishimura, Hiromichi Shirasu
Publikováno v:
International Journal of Clinical Oncology. 26:1822-1830
Distant metastasis is a poor prognostic factor in recurrent/metastatic squamous cell carcinoma of the head and neck. However, limited information on the prognostic impact of locoregional disease is available, despite its life-threatening features. We
Autor:
Satoshi Hamauchi, Akira Andoh, Takahiro Tsushima, Tomoya Yokota, Akiko Todaka, Yusuke Onozawa, Hirofumi Yasui, Akira Fukutomi, Hiromichi Shirasu, Kunihiro Fushiki, Hiroto Inoue, Kentaro Yamazaki, Takeshi Kawakami, Nozomu Machida
Publikováno v:
Investigational New Drugs
SummaryBackground Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC). S-1 is often used as a second-line therapy in clinical practice, based on the results
Autor:
Hitoshi Hirakawa, Yasushi Shimizu, Moriyasu Yamauchi, Akihito Watanabe, Nobuhiro Hanai, Makoto Arai, Naomi Kudo, Ryuji Yasumatsu, Takeharu Ono, Shin Kariya, Masafumi Yoshida, Akinori Fujiwara, Takahiro Asakage, Kiyoaki Tsukahara, Shuji Yonekura, Takashi Fujii, Tomoko Yamazaki, Kenji Hanyu, Takayuki Yamada, Tomoya Yokota, Akihiro Homma, Daisuke Sano, Nobuya Monden, Tsutomu Ueda, Shunji Takahashi, Koichi Omori
Publikováno v:
International Journal of Clinical Oncology
Background To examine the effect of prior use of cetuximab and neck dissection on the effectiveness of nivolumab, we conducted a large-scale subgroup analysis in Japanese patients with recurrent/metastatic head and neck cancer. Methods Data on the ef
Autor:
Shuhei Mayanagi, Keiichi Ohshima, Kenichi Urakami, Eisuke Booka, Shumpei Ohnami, Ken Yamaguchi, Tomoya Yokota, Kenjiro Ishii, Takeshi Nagashima, Yasuhiro Tsubosa
Publikováno v:
Esophagus
Background Recent comprehensive mutation analyses have revealed a relatively small number of driver mutations in esophageal cancer, implicating a limited number of molecular targets, most of which are also implicated in squamous cell carcinoma. Metho
Autor:
Shinichi Okada, Tomoya Yokota, Yuki Irifune, Yusuke Onozawa, Tsuyoshi Onoe, Satoshi Hamauchi, Takashi Mukaigawa, Yoshiyuki Iida, Tetsuro Onitsuka, Tomoyuki Kamijo, H. Shirasu, Kotaro Ishida, Hirofumi Ogawa
Publikováno v:
International Journal of Clinical Oncology. 26:1039-1048
De-escalating treatments have been focused on for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). We assessed the efficacy of a triplet induction chemotherapy (ICT) followed by surgery with or without neck dissection (ND) for locally ad
Autor:
Tetsuo Akimoto, Tomoya Yokota, Hirofumi Fujii, Yosuke Ota, Torahiko Nakashima, Nobuya Monden, Takeshi Kodaira, Shinya Ueda, Mototsugu Shimokawa, Akihiro Homma
Publikováno v:
International Journal of Clinical Oncology. 26:316-325
The aims of this study are to evaluate the efficacy and safety of first-line treatment with chemotherapy plus cetuximab in real-world patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) and to identify progno
Autor:
Susumu Okano, Akihiro Homma, Koichi Yasuda, Kaoru Tanaka, Kazuto Matsuura, Nobuhiro Hanai, Takuma Onoe, Atsushi Motegi, Tomoya Yokota, Yosuke Ariizumi, Shunji Takahashi, Naomi Kiyota, Takahiro Asakage, Takeshi Kodaira, Takenori Ogawa, Yoshinori Imamura, Daisuke Sano, Ryuichi Hayashi, Yuki Saito, Makoto Tahara
Publikováno v:
Japanese Journal of Clinical Oncology. 50:1089-1096
Squamous cell carcinoma of the head and neck is characterized by an immunosuppressive environment and evades immune responses through multiple resistance mechanisms. A breakthrough in cancer immunotherapy employing immune checkpoint inhibitors has ev
Autor:
Hiromichi Shirasu, Hiroto Inoue, Yusuke Onozawa, Hirofumi Yasui, Tetsuro Onitsuka, Akifumi Notsu, Satoshi Hamauchi, Tomoya Yokota, Takeshi Kawakami
Publikováno v:
Auris Nasus Larynx. 47:650-657
Objective Baseline tumor size has been reported to be predictive of immune checkpoint inhibitor efficacy in melanoma and lung cancer. We investigated whether pre-treatment tumor size (PTS) is predictive of progression-free survival (PFS) and tumor sh
Autor:
Makoto Tahara, Yasushi Shimizu, Wing Sum Kenneth Li, Naomi Kiyota, Toshimitsu Endo, Masahiro Goto, Jin Hyoung Kang, Tomoya Yokota, Chia Jui Yen, Vijayvel Jayaprakash, Robert L. Ferris, Ruey-Long Hong, Shunji Takahashi, Maura L. Gillison, Shigemichi Iwae, Nobuhiro Hanai
Publikováno v:
Head & Neck. 42:2852-2862
Background The present study evaluated the 2-year survival of the Asian population in the CheckMate 141 trial. Methods The CheckMate 141 trial included patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Autor:
Tetsuro Onitsuka, Hirofumi Yasui, Tomoyuki Kamijo, Yoshiyuki Iida, Satoshi Hamauchi, Tsuyoshi Onoe, Yusuke Onozawa, Hirofumi Ogawa, Tomoya Yokota
Publikováno v:
International Journal of Clinical Oncology. 25:1596-1603
Definitive radiotherapy (RT) for stage II laryngeal cancer is known to be less effective for locoregional control and survival (LRCS) in patients with high-risk factors (e.g., subglottic extension, impaired cord mobility, or bulky tumor size) than in